# US 2023/0391831 A1 · Formulation for wound healing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0391831 A1
- Document ID: US20230391831A1
- Status: Published application
- Kind: A1
- Application number: 18/032,080
- Filed: 2021-10-13
- Published: 2023-12-07
- Earliest claimed: 2020-10-15
- Applicants: Arizona Board of Regents On Behalf of Arizona State University
- Inventors: Alexandra Lucas; Liqiang Zhang; Jordan Yaron
- Web page: https://patentgrep.com/patent/US20230391831A1

## CPC

- C07K 14/005: from viruses
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2710/24022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/24033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Wound healing is a process by which these wounds on the skin of a subject heal and eventually close. When the injured surface is large, becomes infected, or in patients with poor healing capacity such as diabetics or the elderly or bedridden patients, then wound healing can be prolonged and lead to chronic ulceration and further complications with even limb loss or increased morbidity and mortality. This invention is directed to a topical formulation for promoting wound healing, and wound dressings and bandages comprising the same.

## Claims

### Claim 1

A topical formulation for promoting wound healing, the formulation comprising a therapeutically effective amount of an M-T7 polypeptide.

### Claim 2 (depends on 1)

The topical formulation of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The topical formulation of claim 1, wherein the M-T7 polypeptide comprises a biologically active fragment of M-T7 derived from Myxoma-virus.

### Claim 4 (depends on 1)

The topical formulation of claim 1, wherein the M-T7 polypeptide is recombinantly produced.

### Claim 5 (depends on 1)

The topical formulation of claim 1, wherein the M-T7 polypeptide has an amino acid sequence at least 80% identical to the amino acid sequence of
(SEQ ID NO: 1)
MDGRLVFLLASLAIVSDAVRLTSYDLNTFVTWQDDGYTYNVSIKPYTTA
TWINVCEWASSSCNVSLALQYDLDVVSWARLTRVGKYTEYSLEPTCAVA
RFSPPEVQLVRTGTSVEVLVRHPVVYLRGQEVSVYGHSFCDYDFGYKTI
FLFSKNKRAEYVVPGRYCDNVECRFSIDSQESVCATAVLTYGDSYRSEA
GVEVCVPELAKREVSPYIVKKSSDLEYVKRAIHNEYRLDTSSEGRRLEE
LYLTVASMFERLVEDVFE

### Claim 6 (depends on 1)

The topical formulation of claim 1, wherein the M-T7 polypeptide has an amino acid sequence at least 80% identical to the amino acid sequence of
(SEQ ID NO: 2)
VRLTSYDLNTFVTWQDDGYTYNVSIKPYTTATWINVCEWASSSCNVSLA
LQYDLDVVSWARLTRVGKYTEYSLEPTCAVARFSPPEVQLVRTGTSVEV
LVRHPVVYLRGQEVSVYGHSFCDYDFGYKTIFLFSKNKRAEYVVPGRYC
DNVECRFSIDSQESVCATAVLTYGDSYRSEAGVEVCVPELAKREVSPYI
VKKSSDLEYVKRAIHNEYRLDTSSEGRRLEELYLTVASMFERLVEDVFE

### Claim 7 (depends on 1)

The topical formulation of claim 1, wherein the M-T7 polypeptide lacks the N-terminus secretion sequence.

### Claim 8 (depends on 5, 6)

The topical formulation of claim 5 or claim 6, wherein the M-T7 polypeptide has a minimal amino acid sequence at least 80% identical to a polypeptide fragment within SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 9 (depends on 1)

The topical formulation of claim 1, further comprising one or more additional active ingredients.

### Claim 10 (depends on 9)

The topical formulation of claim 9, wherein the one or more additional active ingredients comprises an antibiotic, a pain reliever, an anti-inflammatory, an anti-scarring agent, a moisturizer, a steroid, an immune modulator, or a growth factor.

### Claim 11 (depends on 1)

The topical formulation of claim 1, wherein the topical formulation is contained in a hydrophilic polymer.

### Claim 12 (depends on 11)

The topical formulation of claim 11, wherein the hydrophilic polymer comprises a hydrogel.

### Claim 13 (depends on 12)

The topical formulation of claim 12, wherein the hydrogel comprises chitosan, collagen, glycerine, aloe vera, methyl paraben, hydrogenated castor oil, hyaluronic acid, polypeptides, pHEMA, pHPMA, or any combination thereof.

### Claim 14 (depends on 1)

The topical formulation of claim 1, wherein the M-T7 polypeptide comprises one or more post-translational modifications.

### Claim 15 (depends on 1)

The topical formulation of claim 1, wherein the M-T7 polypeptide comprises one or more modifications to a post-translational modification.

### Claim 16 (depends on 14, 15)

The topical formulation of claim 14 or 15, wherein the post-translational modification is selected from the group consisting of PEGylation, sialylated, glycosylation, acetylation, acylation, lipid modification, palmitoylation, palmitate addition, phosphorylation, or glycolipid modification.

### Claim 17 (depends on 1)

The topical formulation of claim 1, wherein the M-T7 polypeptide comprises at least one mutation.

### Claim 18 (depends on 1)

The topical formulation of claim 1, wherein the composition is formulated as a topical ointment, cream, lotion, suspension, aqueous solution, dispersion, salve, gel, spray, or paste.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A nucleic acid encoding the M-T7 polypeptide of any one of claims 1-18. The nucleic acid of claim 19, wherein the nucleic acid has a nucleic acid sequence at least 80% identical to the nucleic acid of claim 19.

### Claim 21 (depends on 16)

A vector comprising the nucleic acid of claim 16.

### Claim 22 (depends on 18)

A cell comprising the vector of claim 18.

### Claim 23 (depends on 1)

A wound dressing or bandage comprising a therapeutically effective amount of an M-T7 polypeptide of claim 1, wherein the polypeptide comprises a formulation that is added to, coated, on, or embedded into the wound dressing or bandage.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20)

A method of treating a wound in a subject in need thereof, the method comprising administering topically onto the wound the topical formulation of any one of claims 1-15 or the wound dressing of claim 20 to the wound in the subject.

### Claim 25 (depends on 20)

The method of claim 20, wherein the wound is a dermal wound, a chronic wound, an infected wound, a burn wound, a diabetic wound, a skin wound, or a cutaneous wound.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20)

A method of promoting angiogenesis in a subject in need thereof, the method comprising administering topically onto the wound the topical formulation of any one of claims 1-15 or the wound dressing of claim 20 to the wound in the subject.

### Claim 27 (depends on 1)

A kit comprising the topical formulation according to claim 1.
